[Factors affecting the prognosis of brain tumors].
A variety of tumors with different histologic types are included in a group of brain tumors. Although each histologic type of tumor has its own range of malignancy, the prognosis seems to be affected by several clinical, histologic and cell-biological factors. For example, relative survival rate of patients with glioblastoma is lower if the patient is older than 50 or 60 years. The leptomeningeal dissemination of glioma cells is a sign of poor prognosis. The presence of necrotic foci in the astrocytic tumors suggests shorter astrocytic tumors suggests shorter survival. Using a monoclonal antibody to bromodeoxyuridine (BrdU), the growth activity of the tumor can be estimated by BrdU labeling index (BrdU-LI, %). Higher BrdU-LI is correlated with more malignant histologic features in astrocytic tumors. In meningiomas, higher BrdU-LI is correlated with a more frequent or rapid recurrence of the tumor. The significance of growth factor receptors and oncogene of growth factor receptors and oncogene products as a cell-biologic marker of malignancy was investigated with an immunohistochemical method. Transferrin receptor was demonstrated in all tumors, and epidermal growth factor in about 40% of astrocytic tumors. The immunoreaction to c-myc oncogene product was detected in most astrocytic tumors; with higher intensity in anaplastic astrocytomas and glioblastomas than in low-grade astrocytomas. The role of these markers in the prognosis of brain tumors is, however, still unclear. Total or subtotal resection of glioblastoma results in longer resection of glioblastoma results in longer survival. Both postoperative radiotherapy and chemotherapy are effective. However, maintenance of chemotherapy longer than longer than 2 years does not significantly improve the prognosis.
Yoshimine
T
T
Dept. of Neurosurgery, Osaka University Medical School.
Hayakawa
T
T
Mogami
H
H
D000367:Age Factors; D000911:Antibodies, Monoclonal; D001254:Astrocytoma / Q000032:analysis / Q000401:mortality / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis; D001932:Brain Neoplasms / Q000032:analysis / Q000401:mortality / Q000473:pathology*; D001973:Bromodeoxyuridine; D002453:Cell Cycle; D004815:Epidermal Growth Factor / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis; D005909:Glioblastoma / Q000032:analysis / Q000401:mortality / Q000473:pathology; D006801:Humans; D008579:Meningioma / Q000032:analysis / Q000401:mortality / Q000473:pathology; D009837:Oligodendroglioma / Q000032:analysis / Q000401:mortality / Q000473:pathology; D009857:Oncogenes; D011379:Prognosis
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D001973:Bromodeoxyuridine